X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Transfusion of The First Patients Lab-Grown Blood Cells

    Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Report Indicates UK £62bn Behind In Global R&D Investment

    Wall Street Cautiously Optimistic After Gene Therapy Deals

    Wall Street Cautiously Optimistic After Gene Therapy Deals

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Transfusion of The First Patients Lab-Grown Blood Cells

    Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Report Indicates UK £62bn Behind In Global R&D Investment

    Wall Street Cautiously Optimistic After Gene Therapy Deals

    Wall Street Cautiously Optimistic After Gene Therapy Deals

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Market Moves

AstraZeneca reports the positive Top-Line Results from the Benralizumab Phase III Programme in Severe Asthma

Yuvraj_pawp by Yuvraj_pawp
17th May 2016
in Market Moves

Kyowa Hakko Kirin Co Ltd announced that AstraZeneca obtained the positive top-line results that benralizumab, a potential new medicine and anti-eosinophil monoclonal antibody.                               

 

It was well tolerated and achieved the primary end-point in two pivotal Phase III registrational trials (SIROCCO and CALIMA), demonstrating significant reductions in the annualized asthma exacerbation rate compared to placebo.

 

The trials evaluated the efficacy and safety of two dose regimens of benralizumab as an add-on therapy for severe, uncontrolled asthma with eosinophilic inflammation.

 

In SIROCCO and CALIMA, the primary analysis population included patients on high-dose inhaled corticosteroids (ICS) plus long-acting β2-agonist (LABA) with a baseline blood eosinophil count ≥ 300 cells/microliter. The safety and tolerability findings for benralizumab were generally consistent with those reported in previous studies. Patients were randomized to receive benralizumab 30 mg every 4 weeks; 30 mg every 4 weeks for the first three doses followed by 30 mg every 8 weeks; or placebo

 

“We are delighted with the positive results from these pivotal Phase III studies of benralizumab in patients with uncontrolled asthma. Benralizumab is Kyowa Hakko Kirin’s second product using the POTELLIGENT® technology that enhances the activity of antibody-dependent cell-mediated cytotoxicity (ADCC). We believe benralizumab has the potential to deliver a new therapeutic option for uncontrolled asthma patients with eosinophilic phenotype.” said Yoichi Sato, Managing Executive Officer, Vice President, Head of Research and Development Division of Kyowa Hakko Kirin.

 

Eosinophils are the biological effector cells which drive inflammation and airways hyper-responsiveness in approximately 50% of asthma patients, leading to frequent exacerbations, impaired lung function and reduced quality of life. Benralizumab is an anti-eosinophil monoclonal antibody that depletes eosinophils via ADCC, the process by which natural killer cells are activated to target eosinophils. Benralizumab induces direct, rapid, and near complete depletion of eosinophils in the bone marrow, blood and target tissue

 

Results from the SIROCCO and CALIMA trials will be presented at a future medical meeting. The Kyowa Hakko Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies.

 

About SIROCCO and CALIMA
SIROCCO and CALIMA are both part of the comprehensive WINDWARD programme in asthma, the largest Phase III development programme for a biologic in respiratory disease. (A total of 2,511 patients: 1,205 in SIROCCO and 1,306 in CALIMA)

 

About Benralizumab
Benralizumab is an anti-eosinophil monoclonal antibody that binds to the human interleukin-5 receptor alpha subunit (IL-5Rα) expressed on the surface of eosinophils and basophils. In binding to the receptor, benralizumab leads to active, rapid and direct eosinophil depletion (apoptosis by ADCC) through natural killer cells. Kyowa Hakko Kirin/BioWa have granted to AstraZeneca exclusive development and commercialisation rights for benralizumab in certain countries including the US and Europe and an exclusive option to commercialise benralizumab in Japan and are eligible for milestone payments and royalties related to the development and commercialisation of benralizumab in those countries. Kyowa Hakko Kirin/BioWa have all rights for benralizumab in certain countries in Asia. Kyowa Hakko Kirin retains the rights to participate in certain commercial activities alongside AstraZeneca in Japan when the option is exercised by AstraZeneca.

Previous Post

Chugai Pharmaceutical Co Ltd announced Efficacy of Actemra Subcutaneous Injection Confirmed in Dose Interval Reduction Study in Patients with Rheumatoid Arthritis

Next Post

Merck and Pfizer to Present Avelumab Data in Seven Different Cancers at ASCO Annual Meeting

Related Posts

Grünenthal to buy NebidoTM testosterone treatment from Bayer for €500m
Market Moves

Grünenthal to buy NebidoTM testosterone treatment from Bayer for €500m

18th July 2022
Could The Long Deckline In Biotechnology M&A Be Ending
Featured

Could The Long Deckline In Biotechnology M&A Be Ending

16th July 2022
EMA Advises Recall of AbbVie, Biogen MS Drug
Market Moves

No Rush In Indian Generic Drug Firms To Launch COVID Products

16th July 2022
Market Moves

Gerresheimer raises revenue guidance for 2022 to double-digit growth after strong first quarter

8th April 2022
Regeneron, Intellia to develop CRISPR/Cas9-based treatments
Market Moves

Metagenomi Closes Oversubscribed $175M Series B Financing to Advance Therapeutic Pipeline and Expand Novel Gene Editing Platform

29th January 2022
Charities Pay $6 Million to Settle Medicare Kickback Allegations in Pharma Probe
Market Moves

Indian Pharma Industry To Grow By 9-11% In FY22- ICRA

7th January 2022
Next Post

Merck and Pfizer to Present Avelumab Data in Seven Different Cancers at ASCO Annual Meeting

Latest News

Clinical Trials

Transfusion of The First Patients Lab-Grown Blood Cells

9th November 2022
Clinical Trials

Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

8th November 2022
India Seeks Better Pharma Market Access In The UK: Official
Facilities & Operation

India Seeks Better Pharma Market Access In The UK: Official

8th November 2022
First Virtual Drug Study Tests 2 Likely Alzheimer Therapies
Clinical Trials

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

7th November 2022
CPhI Pharma Index Shows Unprecedented Global Pharma Optimism
Facilities & Operation

CPhI Pharma Index Shows Unprecedented Global Pharma Optimism

5th November 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In